Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

View Full Paper
Ask AI
Bookmark
Share

Authors

ABArielle BaimMedical College of WisconsinCOClaire OligMedical College of WisconsinKFKathryn E. FlynnUniversity of California, San Francisco

Discussion

Loading...

Member takes

Overview

Open-label study shows improved molecular response in patients with chronic myeloid leukemia using asciminib and lowTKI.

Key Points

  • To evaluate the efficacy and safety of asciminib combined with low dose TKIs in chronic myeloid leukemia patients.
  • Multicenter phase 2, single-arm, open-label study
  • Patients received either asciminib 40 mg twice daily or 80 mg once daily
  • Assessment of molecular response rates including MR4 and MR4.5
  • 41.9% achieved MR4 or better at 12 months
  • 12 patients added lowTKI due to various response issues
  • Grade 1-2 adverse events included anemia and thrombocytopenia

Cite This Study

Baim et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6behttps://doi.org/10.1182/blood-2025-7311
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia.2026
  2. 2Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis2025
  3. 3Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results2024 · 55 citations
  4. 4Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase2025
  5. 5Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results2025 · 13 citations